Alyson Paige Barton, NP-C | |
400 W Arbrook Blvd Ste 101, Arlington, TX 76014-3175 | |
(817) 801-1456 | |
Not Available |
Full Name | Alyson Paige Barton |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 400 W Arbrook Blvd Ste 101, Arlington, Texas |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1154090264 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 1056687 (Texas) | Secondary |
363LF0000X | Nurse Practitioner - Family | 1056687 (Texas) | Primary |
Mailing Address | Practice Location Address |
---|---|
Alyson Paige Barton, NP-C 3021 Pin Oak Ln, Bedford, TX 76021-2814 Ph: (817) 307-6286 | Alyson Paige Barton, NP-C 400 W Arbrook Blvd Ste 101, Arlington, TX 76014-3175 Ph: (817) 801-1456 |
News Archive
The presence of special immune system defense molecules, called autoimmune antibodies, has been strongly tied to how poorly people fare when hospitalized with COVID-19, a new study shows.
And now for some good news: Medicare spending growth has been slowing noticeably. ... some evidence suggests it may be a shift toward value in the health-care sector. Various hospital executives have told me they have already begun to prepare for less generous reimbursement from Medicare as the new federal health-care-reform law takes effect.
Extracts of the geranium plant Pelargonium sidoides inactivate human immunodeficiency virus type 1 (HIV-1) and prevent the virus from invading human cells. In the current issue of "PLOS ONE", scientists from the Helmholtz Zentrum München report that these extracts represent a potential new class of anti-HIV-1 agents for the treatment of AIDS.
Principal investigators and clinical trials units have been chosen to lead and conduct the research of five HIV/AIDS clinical trials networks through 2021. The effort is directed and funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Total funding for the networks' leadership and the CTUs is expected to reach $225 million in 2014, the first year of operation.
› Verified 8 days ago